Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
LAVVAN, Inc. v. Amyris, Inc.
Case Number:
1:20-cv-07386
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
September 15, 2022
2nd Circ. Won't Push $881M Cannabis IP Fight Into Arbitration
The Second Circuit on Thursday affirmed a lower court's decision rebuffing biotechnology company Amyris' arbitration bid in cannabinoid maker Lavvan's $881 million patent and trade secrets suit over cannabis development, ruling that a research agreement between the companies doesn't clearly warrant the arbitration.
-
July 26, 2021
Biotech Co. Can't Arbitrate $881M Cannabinoid IP Fight
A New York federal judge on Monday denied biotech company Amyris' bid to arbitrate an $881 million trade secrets fight with cannabinoid manufacturer Lavvan, finding that a prior agreement the parties entered into requires them to litigate intellectual property disputes.
-
October 06, 2020
Biotech Co. Wants $881M Cannabinoid IP Fight Arbitrated
Biotech company Amyris Inc. says cannabinoid manufacturer Lavvan Inc. should be forced to arbitrate its claims in an $881 million trade secrets lawsuit between the companies, or the suit should be tossed altogether.
-
September 10, 2020
Cannabinoid Maker Hits Amyris With $881M Trade Secrets Suit
A cannabinoid manufacturer slapped biotech company Amyris with an $881 million trade secrets suit Thursday, alleging the company inked a research and development agreement to boost its stock price and then reneged on the terms to conceal a "rotten" business model.